Cover Image
市場調查報告書

嚴重急性呼吸道症候群 (SARS) 犬冠狀病毒感染疾病:開發平台分析

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255961
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
嚴重急性呼吸道症候群 (SARS) 犬冠狀病毒感染疾病:開發平台分析 Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 56 Pages
簡介

嚴重急性呼吸道症候群 (SARS)是犬冠狀病毒科的病毒所引起,嚴重時可能致死的可怕病毒傳染病。症狀有咳嗽、發冷和發抖、頭痛、肌肉痛、腹瀉、暈眩、噁心和嘔吐等。危險因素有免疫系統的遺傳基因變異,與感染者的緊密接觸等。

本報告提供嚴重急性呼吸道症候群 (SARS) 犬冠狀病毒感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

嚴重急性呼吸道症候群 (SARS) 犬冠狀病毒感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • Protein Sciences Corporation

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • CEL-1000
  • D-3252
  • Drugs to Inhibit Cathepsin L for Infectious Diseases
  • FDX-000
  • INO-4500
  • LCA-60
  • middle east respiratory syndrome vaccine + severe acute respiratory syndrome vaccine
  • ML-188
  • Monoclonal Antibody for SARS Virus Infections
  • RBD-219N1
  • SARS (virus like particle) vaccine
  • SARS vaccine
  • SARS vaccine
  • severe acute respiratory syndrome vaccine
  • Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections
  • SSYA-10001
  • thiocarbazate

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8351IDB

Summary

Global Markets Direct's, 'Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016', provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS)
  • The report reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Severe Acute Respiratory Syndrome (SARS) therapeutics and enlists all their major and minor projects
  • The report assesses Severe Acute Respiratory Syndrome (SARS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Severe Acute Respiratory Syndrome (SARS) Overview
  • Therapeutics Development
    • Pipeline Products for Severe Acute Respiratory Syndrome (SARS) - Overview
    • Pipeline Products for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis
  • Severe Acute Respiratory Syndrome (SARS) - Therapeutics under Development by Companies
  • Severe Acute Respiratory Syndrome (SARS) - Therapeutics under Investigation by Universities/Institutes
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Severe Acute Respiratory Syndrome (SARS) - Products under Development by Companies
  • Severe Acute Respiratory Syndrome (SARS) - Products under Investigation by Universities/Institutes
  • Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
    • CEL-SCI Corporation
    • GeneCure LLC
    • Inovio Pharmaceuticals, Inc.
    • Nanotherapeutics, Inc.
    • Novavax, Inc.
    • Phelix Therapeutics, LLC
    • Planet Biotechnology Inc.
    • Protein Sciences Corporation
  • Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-3252 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-4500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome coronavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ML-188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for SARS Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBD-219N1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SARS (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSYA-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
  • Severe Acute Respiratory Syndrome (SARS) - Discontinued Products
  • Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 19, 2015: Inovio and Partner Advance MERS Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016
  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corporation, H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax, Inc., H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics, LLC, H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Planet Biotechnology Inc., H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Protein Sciences Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects (Contd..1), H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects (Contd..2), H2 2016
  • Severe Acute Respiratory Syndrome (SARS) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016
  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top